About thirty hospitals across the UK are to seek patients out who are willing to take part in the analysis of the new drugs.
As the hunt for coronavirus treatment continues, thirty hospitals are to pre-test five new drugs. Following the suspension of hydroxychloroquine trials which was prompted by President Donald Trump, scientists in the UK are looking to sign up many patients for trials of the new prevention drugs.
The British scientists believe that the new medicines will help prevent people from being infirmed enough to need intensive care or ventilators.
The analysis of the medicines is part of the Accord (accelerating Covid-19 research and development) programme including doctors and scientists, industry, the NHS, the National Institute of Health Research (NIHR) and the UK Research and Innovation.
A respiratory medicine professor and consultant, who is the Accord academic lead, from the NIHR Southampton Biomedical Research Centre, Tom Wilkinson said: “We are looking for a signal of both safety and efficacy, something that could reduce the severity of the disease, shorten its duration and prevent patients going into the intensive care environment.”
“These are small, rapidly deliverable studies if we get patients in so we’re looking only to achieve around 60 patients for each arm of the trial to receive one of the drugs compared to usual standard of care,” he added.
Among the drugs to be tested is Heparin, Bemcentinib, Medi3506, Calquence and Zilucoplan.
Several hospitals like St Thomas` where Prime Minister Boris Johnson was treated and Guy`s in London, as well as major hospitals in Liverpool, Manchester, Leeds, Leicester and Glasgow, are taking part, so as Southend and other coastal hospitals.
Although reducing the number of infections is almost everyone`s desire, the decrease presents a problem to the scientists researching treatments and vaccines.